From DCAT Value Chain Insights (VCI)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company specializing in rare-disease drug development, has appointed David L. Hallal as the company’s chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexion’s chief operating officer (COO) and is a director of the board. He will succeed Leonard Bell, MD, chairman and CEO, who will retire as CEO and continue to serve as chairman of the board. Dr. Bell was the principal founder of Alexion in 1992 and has served as CEO for the past 23 years.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Since joining Alexion in 2006 to initiate commercial operations, he has served in key leadership positions of increasing responsibility, including as the company’s first chief commercial ffficer, and was appointed COO and to the Board of Directors in 2014.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription